ImmunoCellular Seeing Action on News Items
Insights - ImmunoCellular Therapeutics’ (IMUC) stock is up 24% on Monday following ROTH Capital’s price target raise, to $9 (from $6), the firm adding the stock to its … Continue Reading
PremiumAuthor Archives: Jake King
“Greed is Good”: Hologic Attracts the Value Crowd
Research - This article was published for PropThink’s Premium members on Friday, November 22. Hologic (HOLX) gapped up last Thursday morning after activist investor Carl Icahn reported … Continue Reading
Read now
Canadian Acquisitions: QLT Inc. Fits the Trend
Research - It seems QLT Inc. may be on the block after a press release on Wednesday evening indicated the company has engaged Credit Suisse as a … Continue Reading
Read now
No News for QLTI, Yet the Stock is Going
Research - Note: This article was sent to PropThink Premium members during the afternoon of November 20, 2013. Also see our follow-up commentary here. In morning trading, … Continue Reading
Premium
This Antibiotic Play May Be the Trius of 2014
Research - 2013 has been a year of change in the landscape for publicly traded antibiotic developers, driven by Cubist Pharmaceuticals’ (CBST) high-profile acquisitions of competitors Trius … Continue Reading
Read now
Sarepta Dives on FDA Commentary
Insights - Sarepta Therapeutics (SRPT) revealed on Tuesday that the U.S. FDA wants the company to run a phase 3 trial before submitting a New Drug Application … Continue Reading
Premium
The Long Case for Zogenix
Research - Zogenix (ZGNX) expects to net $56 million from a secondary offering revealed on November 4, $64.4 million with full exercise of the underwriter’s over-allotment option. … Continue Reading
Read now